Search
Find out why people at risk of lung cancer are not getting screened and why they should.
Descubra por qué las personas con riesgo de cáncer pulmonar no se están realizando la prueba de detección y por qué deberían hacerlo.
Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.
Sacral neuromodulation has already helped patients with benignly caused fecal incontinence – can it do the same for rectal cancer patients following sphincter-preserving surgery?
Immune checkpoint inhibitors and adoptive T cell therapy have shown success in treating several cancers. Now both approaches are in trials for gynecologic cancers, and researchers think even more applications are possible.
In these incredibly challenging times, healthcare workers are our real-life superheroes! Here at Memorial Sloan Kettering, our amazing staff is working around the clock to keep doing what we do best: providing safe and exceptional care to patients with cancer. From doctors and nurses to security, patient transporters, and cleaning staff, our entire team at MSK remains fiercely dedicated to our mission.
Experts from MSK explain why seed oils are actually an important part of a healthy diet.
An international phase 3 trial has found that polatuzumab vedotin improves outcomes for patients with newly diagnosed diffuse large B cell lymphoma.
NEW YORK, September 21, 2003 - New research from Memorial Sloan Kettering Cancer Center (MSKCC), Cornell University, and The University of Connecticut describes a novel way of producing therapeutic nerve cells that can cure mice with Parkinson's-like disease. The work, which will be published in the October issue of Nature Biotechnology (available online September 21), provides the first evidence that cloned cells can cure disease in an animal model.